462 related articles for article (PubMed ID: 29396246)
1. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
[TBL] [Abstract][Full Text] [Related]
2. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
3. Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.
Lanzolla G; Sabini E; Leo M; Menconi F; Rocchi R; Sframeli A; Piaggi P; Nardi M; Marcocci C; Marinò M
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):733-742. PubMed ID: 34592164
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tripterygium glycosides for active moderate to severe Graves' ophthalmopathy: a randomised, observer-masked, single-centre trial.
Ye X; Zhao H; Liu J; Lu B; Shao J; Wang J
Eur J Endocrinol; 2021 Feb; 184(2):277-287. PubMed ID: 33539318
[TBL] [Abstract][Full Text] [Related]
5. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
6. Systemic safety analysis of mycophenolate in Graves' orbitopathy.
Lee ACH; Riedl M; Frommer L; Diana T; Kahaly GJ
J Endocrinol Invest; 2020 Jun; 43(6):767-777. PubMed ID: 31834613
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
8. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial.
Rajendram R; Taylor PN; Wilson VJ; Harris N; Morris OC; Tomlinson M; Yarrow S; Garrott H; Herbert HM; Dick AD; Cook A; Gattamaneni R; Jain R; Olver J; Hurel SJ; Bremner F; Drummond SR; Kemp E; Ritchie DM; Rumsey N; Morris D; Lane C; Palaniappan N; Li C; Pell J; Hills R; Ezra DG; Potts MJ; Jackson S; Rose GE; Plowman N; Bunce C; Uddin JM; Lee RWJ; Dayan CM
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):299-309. PubMed ID: 29396245
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P
J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy.
Bartalena L; Krassas GE; Wiersinga W; Marcocci C; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Veronesi G; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G;
J Clin Endocrinol Metab; 2012 Dec; 97(12):4454-63. PubMed ID: 23038682
[TBL] [Abstract][Full Text] [Related]
11. Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.
Schmidt-Kraepelin C; Feyerabend S; Engelke C; Riesbeck M; Meisenzahl-Lechner E; Verde PE; Correll CU; Kluge M; Makiol C; Neff A; Lange C; Englisch S; Zink M; Langguth B; Poeppl TB; Reske D; Gouzoulis-Mayfrank E; Gründer G; Hasan A; Brockhaus-Dumke A; Jäger M; Baumgärtner J; Leucht S; Cordes J;
Lancet Psychiatry; 2022 Apr; 9(4):291-306. PubMed ID: 35276079
[TBL] [Abstract][Full Text] [Related]
12. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
13. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study.
Ng CM; Yuen HK; Choi KL; Chan MK; Yuen KT; Ng YW; Tiu SC
Hong Kong Med J; 2005 Oct; 11(5):322-30. PubMed ID: 16219950
[TBL] [Abstract][Full Text] [Related]
14. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
[TBL] [Abstract][Full Text] [Related]
15. Low-Dose Rituximab for Active Moderate to Severe Graves' Orbitopathy Resistant to Conventional Treatment.
Du Pasquier-Fediaevsky L; Andrei S; Berche M; Leenhardt L; Héron E; Rivière S
Ocul Immunol Inflamm; 2019; 27(5):844-850. PubMed ID: 29652204
[No Abstract] [Full Text] [Related]
16. Success Treatment of Severe and Active Graves' Orbitopathy with Tocilizumab After Thyroidectomy and Maximum Dose of Intravenous Methylprednisolone.
Pramono LA
Acta Med Indones; 2023 Oct; 55(4):475-477. PubMed ID: 38213047
[TBL] [Abstract][Full Text] [Related]
17. Prospective, systematically recorded mycophenolate safety data in Graves' orbitopathy.
Riedl M; Kuhn A; Krämer I; Kolbe E; Kahaly GJ
J Endocrinol Invest; 2016 Jun; 39(6):687-94. PubMed ID: 26886940
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy.
Ye X; Bo X; Hu X; Cui H; Lu B; Shao J; Wang J
Clin Endocrinol (Oxf); 2017 Feb; 86(2):247-255. PubMed ID: 27484048
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
[TBL] [Abstract][Full Text] [Related]
20. A pilot study on the use of prednisolone-encapsulated liposomes for the treatment of moderate-to-severe Graves' orbitopathy with reduced systemic steroid exposure.
Detiger SE; Kremer TM; A S H Dalm V; de Keizer ROB; Wubbels RJ; Metselaar JM; van Hagen PM; Peeters RP; Paridaens D
Acta Ophthalmol; 2021 Nov; 99(7):797-804. PubMed ID: 33423386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
